Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study 替米沙坦联合普罗布考可有效降低2型糖尿病肾病患者尿蛋白:一项随机、双盲、安慰剂对照、多中心临床研究

详细信息    查看全文

• 作者：Hanyu Zhu ; Xiangmei Chen ; Guangyan Cai ; Ying Zheng ; Moyan Liu ; Wenhu Liu ; Hebin Yao ; Yaping Wang ; Wenge Li ; Hua Wu ; Lide Lun ; Jianrong Zhang ; Xiaohong Guan ; Shinan Yin ; Xiaoming Zhuang ; Jijun Li ; Yanjun Liu and Chunhua Zhou
• 刊名：Journal of Diabetes
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：8
• 期：5
• 页码：677-685
• 全文大小：314K
• ISSN：1753-0407

文摘

Persistent proteinuria is an important factor contributing to the progression of diabetic nephropathy. The present randomized double-blind placebo-controlled multicenter clinical study evaluated the efficacy and safety of telmisartan combined with the antioxidant probucol in reducing urinary protein levels in patients with type 2 diabetes (T2D).